Alkem Laboratories has received an Establishment Inspection Report from the US Food and Drug Administration for its manufacturing facility at Amaliya, Daman. The US drug authority had conducted the inspection between March 19 and 27 and issued 13 observations. Alkem Labs had submitted a detailed corrective and preventive action plan to the regulator within the stipulated timelines. The inspection has now been closed by the US FDA. Shares of Alkem Lab are likely to remain in focus.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.